PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 7815420-2 1994 ApoCII serves as cofactor for lipoprotein lipase (LPL) in triglyceride hydrolysis of chylomicrons and very low density lipoproteins. Triglycerides 58-70 apolipoprotein C2 Homo sapiens 0-6 1451339-6 1992 PTH and insulin showed a positive correlation with TG, the former being also inversely related to apo-CII/apo-CIII ratio. Triglycerides 51-53 apolipoprotein C2 Homo sapiens 98-105 8020477-3 1994 Apolipoprotein CII increased the maximal inactivation rate constant by 1.8-fold in the presence of an emulsion of long-chain triacylglycerols, but had no effect in the presence of an emulsion of tributyrylglycerol. Triglycerides 125-141 apolipoprotein C2 Homo sapiens 0-18 8301229-7 1993 The synergistic effect of apoC-II and albumin resulted in the preferential activation of LPL for the hydrolysis of long-chain triacylglycerols. Triglycerides 126-142 apolipoprotein C2 Homo sapiens 26-33 8245727-2 1993 As the concentrations of acceptor triglycerides were increased, a greater fraction of both apoC-II and apoC-III shifted away from the native plasma lipoproteins to the artificial lipid emulsions. Triglycerides 34-47 apolipoprotein C2 Homo sapiens 91-98 8350216-0 1993 Relationship between plasma triglycerides and apolipoprotein CII in infants during the first year of life. Triglycerides 28-41 apolipoprotein C2 Homo sapiens 46-64 34458211-10 2021 Plasma levels of apoC-II and apoC-III were positively correlated with total cholesterol, triglyceride, and low-density lipoprotein (LDL) (all p < 0.001). Triglycerides 89-101 apolipoprotein C2 Homo sapiens 17-24 1619390-8 1992 Characterization of these defects has provided new insights into the structure and function of apoC-II and LPL and established the important role that these two proteins play in normal triglyceride metabolism. Triglycerides 185-197 apolipoprotein C2 Homo sapiens 95-102 1804473-2 1991 This study was undertaken to investigate whether the capacity of high-density lipoprotein (HDL) for donating apoCII and apoCIII is influenced by the concentration of triglycerides (TGs) in plasma. Triglycerides 166-179 apolipoprotein C2 Homo sapiens 109-115 1452137-8 1992 It is suggested that the elevated plasma VLDL-TG concentration in endogenous hypertriglyceridemia may induce abnormal redistribution of lipid and apolipoprotein among apoCII plasma lipoproteins, and and CIII may play an important role in these changes. Triglycerides 46-48 apolipoprotein C2 Homo sapiens 167-173 2307668-15 1990 We hypothesize that apoA-IV is required for efficient release of apoC-II from either HDL or VLDL, which then allows for LPL-mediated hydrolysis of TG in nascent chylomicrons. Triglycerides 147-149 apolipoprotein C2 Homo sapiens 65-72 6093789-1 1984 Apolipoprotein C-II (apoC-II), a 79 amino acid protein, is a cofactor for lipoprotein lipase, the enzyme which catalyzes the lipolysis of triglycerides on plasma chylomicrons and VLDL. Triglycerides 138-151 apolipoprotein C2 Homo sapiens 0-19 34459127-3 2021 As apolipoprotein C2 (APOC2) is a key activator of lipoprotein lipase for triglyceride metabolism, the exact mechanism of APOC2 remains largely unknown in GC. Triglycerides 74-86 apolipoprotein C2 Homo sapiens 22-27 3411241-3 1988 Both apoC-II and apoC-III levels increased in VLDL as VLDL apolipoprotein B (apoB) and triglyceride levels rose. Triglycerides 87-99 apolipoprotein C2 Homo sapiens 5-12 3411241-5 1988 Univariate analysis demonstrated that the FCR for VLDL triglyceride was inversely related to the ratio of apoC-III/apoC-II in VLDL (r = -0.58; P less than 0.05), although this relationship was not significant in a multivariate analysis. Triglycerides 55-67 apolipoprotein C2 Homo sapiens 106-113 6433686-5 1984 Controlling for Apo C-II reduced the black-white differences in total cholesterol 87%, LDL cholesterol 44%, VLDL cholesterol 83%, and total triglyceride 83%. Triglycerides 140-152 apolipoprotein C2 Homo sapiens 16-24 3944267-11 1986 The reduction in plasma triglycerides after the injection of the synthetic apo C-II peptide persisted for 13-20 d. These results definitively established that the dyslipoproteinemia in this syndrome is due to a deficiency of normal apo C-II. Triglycerides 24-37 apolipoprotein C2 Homo sapiens 75-83 3944267-11 1986 The reduction in plasma triglycerides after the injection of the synthetic apo C-II peptide persisted for 13-20 d. These results definitively established that the dyslipoproteinemia in this syndrome is due to a deficiency of normal apo C-II. Triglycerides 24-37 apolipoprotein C2 Homo sapiens 232-240 4058312-7 1985 In both groups, TRL apoC-II and apoC-III levels were positively correlated with the triglyceride level as it increased following the corn oil meal. Triglycerides 84-96 apolipoprotein C2 Homo sapiens 20-27 3970943-7 1985 The mechanism of activation of the enzyme at low concentrations of apolipoprotein C-II is described by a kinetic model in which apolipoprotein C-II binds preferentially to the form of the enzyme which is associated with the triacylglycerol substrate. Triglycerides 224-239 apolipoprotein C2 Homo sapiens 67-86 3970943-7 1985 The mechanism of activation of the enzyme at low concentrations of apolipoprotein C-II is described by a kinetic model in which apolipoprotein C-II binds preferentially to the form of the enzyme which is associated with the triacylglycerol substrate. Triglycerides 224-239 apolipoprotein C2 Homo sapiens 128-147 6093789-1 1984 Apolipoprotein C-II (apoC-II), a 79 amino acid protein, is a cofactor for lipoprotein lipase, the enzyme which catalyzes the lipolysis of triglycerides on plasma chylomicrons and VLDL. Triglycerides 138-151 apolipoprotein C2 Homo sapiens 21-28 194919-10 1977 Plasma triglycerides correlated inversely with the fraction of total apoCII in very low density lipoprotein (VLDL)-free plasma (r = -0.75, P < 0.01). Triglycerides 7-20 apolipoprotein C2 Homo sapiens 69-75 7158381-6 1982 A correlation was found between triglyceride concentration in the VLDL fraction and the relative amounts of Apo CII and Apo CIII1. Triglycerides 32-44 apolipoprotein C2 Homo sapiens 108-115 7276752-3 1981 VLDLp binds apoC-II, and apoC-II associated with VLDLp markedly increases the rate of lipoprotein lipase-catalyzed hydrolysis of VLDLp-triglycerides. Triglycerides 135-148 apolipoprotein C2 Homo sapiens 12-19 7276752-3 1981 VLDLp binds apoC-II, and apoC-II associated with VLDLp markedly increases the rate of lipoprotein lipase-catalyzed hydrolysis of VLDLp-triglycerides. Triglycerides 135-148 apolipoprotein C2 Homo sapiens 25-32 7276752-5 1981 ApoC-II causes pH-dependent changes in both apparent Km and VmaX of LpL-catalyzed hydrolysis of VLDLp-triglycerides. Triglycerides 102-115 apolipoprotein C2 Homo sapiens 0-7 7276752-10 1981 Based on a simple kinetic model, the data suggest that apoC-II favors direct interaction between enzyme and triglyceride within the lipoprotein particle, as well as subsequent catalytic turnover. Triglycerides 108-120 apolipoprotein C2 Homo sapiens 55-62 7276737-5 1981 During perfusion, a 50% hydrolysis of the VLDL triacylglycerols was associated with the appearance of 11% of the apoC-II, 30% of the apoC-III, and 20% of apoE of the VLDL in HDL-like particles as isolated by agarose gel filtration. Triglycerides 47-63 apolipoprotein C2 Homo sapiens 113-120 6087809-1 1984 Human apolipoprotein (apo) C-II, a 79 amino acid protein, functions as a cofactor for lipoprotein lipase, the enzyme which catalyzes the hydrolysis of plasma triglycerides. Triglycerides 158-171 apolipoprotein C2 Homo sapiens 6-31 6872264-6 1983 These data suggest that in vivo a precursor-product relationship exists between triglyceride rich lipoproteins and LDL and HDL, and further stress the role of the lipoprotein lipase-apo C-II system in modulating these metabolic interconversions. Triglycerides 80-92 apolipoprotein C2 Homo sapiens 182-190 7138621-14 1982 In heterozygotes, the partial deficiency of Apo C-II appears to result in a minor disturbance of the clearance of the triglycerides and Apo C-III rich particles but no marked changes in the concentrations of total lipids, lipoproteins and apolipoproteins in fasting plasma. Triglycerides 118-131 apolipoprotein C2 Homo sapiens 44-52 449689-0 1979 Availability of apolipoprotein CII in relation to the maximal removal capacity for an infused triglyceride emulsion in man. Triglycerides 94-106 apolipoprotein C2 Homo sapiens 16-34 194919-14 1977 As plasma triglycerides and apoCII increase, apoCII is redistributed from high density lipoprotein to VLDL. Triglycerides 10-23 apolipoprotein C2 Homo sapiens 45-51 178329-3 1976 There were highly significant correlations between the concentration of VLDL triglycerides and apo CII (r---0.92), apo CIII1 (r=+0.88) and the ratio apo CII/apo CIII1 (r= --0.94). Triglycerides 77-90 apolipoprotein C2 Homo sapiens 95-102 178329-4 1976 It was suggested that the decreasing ratio apo CII/CIII1 with increasing triglyceride levels might cause a resistance to lipoprotein lipase and therefore a defect lipolysis of VLDL based upon a changed ratio apo CII/apo CII1 might be part of the pathogenesis of the hypertriglyceridaemia. Triglycerides 73-85 apolipoprotein C2 Homo sapiens 43-50 178329-4 1976 It was suggested that the decreasing ratio apo CII/CIII1 with increasing triglyceride levels might cause a resistance to lipoprotein lipase and therefore a defect lipolysis of VLDL based upon a changed ratio apo CII/apo CII1 might be part of the pathogenesis of the hypertriglyceridaemia. Triglycerides 73-85 apolipoprotein C2 Homo sapiens 208-215 33934596-1 2021 Triglyceride hydrolysis by lipoprotein lipase (LPL), regulated by apolipoproteins C-II (apoC-II) and C-III (apoC-III), is essential for maintaining normal lipid homeostasis. Triglycerides 0-12 apolipoprotein C2 Homo sapiens 66-86 33934596-1 2021 Triglyceride hydrolysis by lipoprotein lipase (LPL), regulated by apolipoproteins C-II (apoC-II) and C-III (apoC-III), is essential for maintaining normal lipid homeostasis. Triglycerides 0-12 apolipoprotein C2 Homo sapiens 88-95 33934596-9 2021 These results suggest that both apoC-II and apoC-III transfer disproportionately from VLDL to HDL2 and the larger HDL3, and these transfers might be involved in individual triglyceride metabolism. Triglycerides 172-184 apolipoprotein C2 Homo sapiens 32-39 30863636-2 2019 We previously reported that a human apoC-II mimetic peptide (C-II-a) decreased plasma TG in apoC-II mutant mice, as well as in apoE-knockout mice. Triglycerides 86-88 apolipoprotein C2 Homo sapiens 36-43 31935511-2 2020 In cardiovascular and cerebrovascular systems, the lipolytic activity of the LPL-ApoC2 complex is critical for the metabolism of triglyceride-rich lipoproteins and contributes to the pathogenesis of ischemic stroke (IS). Triglycerides 129-141 apolipoprotein C2 Homo sapiens 81-86 32562799-1 2020 RATIONALE: ApoC2 is an important activator for lipoprotein lipase-mediated hydrolysis of triglyceride-rich plasma lipoproteins. Triglycerides 89-101 apolipoprotein C2 Homo sapiens 11-16 32793115-3 2020 At the genetic level, severely elevated triglyceride levels resulting from familial chylomicronemia syndrome (FCS) are caused by homozygous or biallelic loss-of-function variants in LPL, APOC2, APOA5, LMF1, and GPIHBP1 genes. Triglycerides 40-52 apolipoprotein C2 Homo sapiens 187-192 32802915-1 2020 Apolipoprotein C2 (ApoC2) is a key activator of lipoprotein lipase for plasma triglyceride metabolism. Triglycerides 78-90 apolipoprotein C2 Homo sapiens 0-17 32802915-1 2020 Apolipoprotein C2 (ApoC2) is a key activator of lipoprotein lipase for plasma triglyceride metabolism. Triglycerides 78-90 apolipoprotein C2 Homo sapiens 19-24 32332429-1 2020 PURPOSE OF REVIEW: Apolipoprotein C-II (apoC-II) is a critical cofactor for the activation of lipoprotein lipase (LPL), a plasma enzyme that hydrolyzes triglycerides (TG) on TG-rich lipoproteins (TRL). Triglycerides 152-165 apolipoprotein C2 Homo sapiens 19-38 32332429-1 2020 PURPOSE OF REVIEW: Apolipoprotein C-II (apoC-II) is a critical cofactor for the activation of lipoprotein lipase (LPL), a plasma enzyme that hydrolyzes triglycerides (TG) on TG-rich lipoproteins (TRL). Triglycerides 152-165 apolipoprotein C2 Homo sapiens 40-47 32332429-1 2020 PURPOSE OF REVIEW: Apolipoprotein C-II (apoC-II) is a critical cofactor for the activation of lipoprotein lipase (LPL), a plasma enzyme that hydrolyzes triglycerides (TG) on TG-rich lipoproteins (TRL). Triglycerides 167-169 apolipoprotein C2 Homo sapiens 19-38 32332429-1 2020 PURPOSE OF REVIEW: Apolipoprotein C-II (apoC-II) is a critical cofactor for the activation of lipoprotein lipase (LPL), a plasma enzyme that hydrolyzes triglycerides (TG) on TG-rich lipoproteins (TRL). Triglycerides 167-169 apolipoprotein C2 Homo sapiens 40-47 32332431-5 2020 Other approaches to reducing circulating triglyceride levels have been using an apoC2 mimetic and reducing apoC3. Triglycerides 41-53 apolipoprotein C2 Homo sapiens 80-85 30863636-2 2019 We previously reported that a human apoC-II mimetic peptide (C-II-a) decreased plasma TG in apoC-II mutant mice, as well as in apoE-knockout mice. Triglycerides 86-88 apolipoprotein C2 Homo sapiens 92-99 29100061-0 2017 Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism. Triglycerides 81-93 apolipoprotein C2 Homo sapiens 0-19 29206648-7 2018 The positive relationship between plasma protein S levels and apoC-II, a key regulator of triglycerides hydrolysis, may contribute to the pathogenesis of increased concentrations of plasma protein S. Triglycerides 90-103 apolipoprotein C2 Homo sapiens 62-69 29100061-2 2017 ApoC-II plays a critical role in TRL metabolism by acting as a cofactor of lipoprotein lipase (LPL), the main enzyme that hydrolyses plasma triglycerides (TG) on TRL. Triglycerides 140-153 apolipoprotein C2 Homo sapiens 0-7 29100061-2 2017 ApoC-II plays a critical role in TRL metabolism by acting as a cofactor of lipoprotein lipase (LPL), the main enzyme that hydrolyses plasma triglycerides (TG) on TRL. Triglycerides 155-157 apolipoprotein C2 Homo sapiens 0-7 28314859-2 2017 This study describes the mechanisms responsible for TG lowering by examining the kinetics of VLDL-TG, apoC-II, apoC-III, and apoE. Triglycerides 52-54 apolipoprotein C2 Homo sapiens 102-109 27378472-4 2016 RESULTS: Plasma apoC-II and apoC-III concentrations were positively associated with the concentrations of plasma triglycerides, VLDL1 - and VLDL2 -apoB-100 and triglyceride (all P < 0 05). Triglycerides 113-126 apolipoprotein C2 Homo sapiens 16-23 28107429-2 2017 Apolipoprotein C-II (APOC2) is an obligatory cofactor for lipoprotein lipase (LPL), the major enzyme catalyzing plasma triglyceride hydrolysis. Triglycerides 119-131 apolipoprotein C2 Homo sapiens 0-19 28107429-2 2017 Apolipoprotein C-II (APOC2) is an obligatory cofactor for lipoprotein lipase (LPL), the major enzyme catalyzing plasma triglyceride hydrolysis. Triglycerides 119-131 apolipoprotein C2 Homo sapiens 21-26 27378472-5 2016 ApoC-II production rate (PR) was positively associated with VLDL1 -apoB-100 concentration, VLDL1 triglyceride concentration and VLDL1 triglyceride PR, while apoC-II fractional catabolic rate (FCR) was positively associated with VLDL1 triglyceride FCR (all P < 0 05). Triglycerides 97-109 apolipoprotein C2 Homo sapiens 0-7 27378472-5 2016 ApoC-II production rate (PR) was positively associated with VLDL1 -apoB-100 concentration, VLDL1 triglyceride concentration and VLDL1 triglyceride PR, while apoC-II fractional catabolic rate (FCR) was positively associated with VLDL1 triglyceride FCR (all P < 0 05). Triglycerides 134-146 apolipoprotein C2 Homo sapiens 0-7 27378472-5 2016 ApoC-II production rate (PR) was positively associated with VLDL1 -apoB-100 concentration, VLDL1 triglyceride concentration and VLDL1 triglyceride PR, while apoC-II fractional catabolic rate (FCR) was positively associated with VLDL1 triglyceride FCR (all P < 0 05). Triglycerides 134-146 apolipoprotein C2 Homo sapiens 0-7 27378472-9 2016 In multivariable analysis, including homoeostasis model assessment score, menopausal status and obesity, apoC-II concentration was significantly associated with plasma triglyceride, VLDL1 -apoB-100 and VLDL1 triglyceride concentrations and PR. Triglycerides 168-180 apolipoprotein C2 Homo sapiens 105-112 27378472-9 2016 In multivariable analysis, including homoeostasis model assessment score, menopausal status and obesity, apoC-II concentration was significantly associated with plasma triglyceride, VLDL1 -apoB-100 and VLDL1 triglyceride concentrations and PR. Triglycerides 208-220 apolipoprotein C2 Homo sapiens 105-112 27378472-4 2016 RESULTS: Plasma apoC-II and apoC-III concentrations were positively associated with the concentrations of plasma triglycerides, VLDL1 - and VLDL2 -apoB-100 and triglyceride (all P < 0 05). Triglycerides 113-125 apolipoprotein C2 Homo sapiens 16-23 26756862-1 2016 Lipoprotein lipase (LPL)-mediated triacylglycerol (TAG) hydrolysis in very low density lipoprotein (VLDL) is accompanied by the release of surface material containing phospholipids (PL), free cholesterol (FC) and apolipoproteins, E (apoE) and Cs (apoCII, apoCIII). Triglycerides 34-49 apolipoprotein C2 Homo sapiens 247-253 27206937-3 2016 OBJECTIVE: To examine the genetic variants of 3 candidate genes known to influence triglyceride metabolism, LPL, APOC2, and APOA5, which encode lipoprotein lipase, apolipoprotein C-II, and apolipoprotein A-V, respectively, in a large group of Thai subjects with severe hypertriglyceridemia. Triglycerides 83-95 apolipoprotein C2 Homo sapiens 164-183 23470567-4 2013 METHODS: We performed detailed biochemical/genetic analyses of our new case of hypoapoC-II, manifesting severe hypertriglyceridemia (plasma triglycerides, 3235 mg dL(-1)) with markedly reduced levels of plasma apoC-II (0.6 mg dL(-1)). Triglycerides 140-153 apolipoprotein C2 Homo sapiens 83-90 23990203-7 2013 Triglyceride (TG)-metabolism-related markers (TG, remnant-like particle cholesterol, apolipoprotein [apo] B, apoC-2, and apoC-3) had decreased significantly. Triglycerides 0-12 apolipoprotein C2 Homo sapiens 109-115 26026161-4 2015 ApoC-II adsorption to a triacylglycerol/water interface resulted in large increases in surface pressure. Triglycerides 24-39 apolipoprotein C2 Homo sapiens 0-7 26026161-8 2015 We characterized apoC-II at phospholipid/triacylglycerol/water interfaces, which more closely mimic lipoprotein surfaces. Triglycerides 41-56 apolipoprotein C2 Homo sapiens 17-24 22262056-7 2012 In liver and small intestine, CREB-H induces LPL coactivators, Apoa4, Apoa5, and Apoc2 that facilitate triglyceride clearance from plasma. Triglycerides 103-115 apolipoprotein C2 Homo sapiens 81-86 22304839-8 2012 Furthermore, excess apoC-II has been associated with increased triglyceride-rich particles and alterations in HDL particle distribution, factors that may increase the risk of CVD. Triglycerides 63-75 apolipoprotein C2 Homo sapiens 20-27 22304839-11 2012 An excess of apoC-II is associated with increased triglyceride-rich particles and alterations in HDL particle distribution. Triglycerides 50-62 apolipoprotein C2 Homo sapiens 13-20 18450649-6 2008 In youths, evidence of association between rs9322331 and rs9340799 and apoC-II was stronger in males (P = 0.0036 and P = 0.0124) than in females (P > 0.05), whereas evidence of association with TG was stronger in females (P = 0.0030 and P = 0.0024) than in males (P > 0.05). Triglycerides 197-199 apolipoprotein C2 Homo sapiens 71-78 21291744-9 2008 Multivariate analysis showed that in O group"s baseline TG levels were independently positively correlated, whereas the baseline ApoC-II levels were negatively correlated with TG-lowering. Triglycerides 176-178 apolipoprotein C2 Homo sapiens 129-136 21291744-12 2008 CONCLUSIONS: Orlistat-mediated TG-lowering is independently associated with baseline TG and ApoC-II levels. Triglycerides 31-33 apolipoprotein C2 Homo sapiens 92-99 22808166-1 2012 Apolipoprotein CII (apoCII) is a specific activator of lipoprotein lipase and plays an important role in triglyceride metabolism. Triglycerides 105-117 apolipoprotein C2 Homo sapiens 0-18 22808166-1 2012 Apolipoprotein CII (apoCII) is a specific activator of lipoprotein lipase and plays an important role in triglyceride metabolism. Triglycerides 105-117 apolipoprotein C2 Homo sapiens 20-26 19302807-13 2009 Furthermore, LPL and ApoC-II secretion induced by fucoidan may be involved in regulating plasma triglyceride lowering clearance. Triglycerides 96-108 apolipoprotein C2 Homo sapiens 21-28 12678662-9 2003 APOCI I/I homozygotes have the highest level of triglycerides (p<0.003). Triglycerides 48-61 apolipoprotein C2 Homo sapiens 0-7 16314153-5 2006 Cleavage of apoC-II by MMP-14 markedly decreased LPL activity and would thus impair hydrolysis of triglycerides in plasma and transfer of fatty acids to tissues. Triglycerides 98-111 apolipoprotein C2 Homo sapiens 12-19 12855707-3 2003 ApoCII prevented the inhibition by bis-ANS, and was also able to restore the activity of inhibited LPL in a competitive manner, but only with triacylglycerols with acyl chains longer than three carbons. Triglycerides 142-158 apolipoprotein C2 Homo sapiens 0-6 16782082-1 2006 BACKGROUND: Apolipoprotein C-II and apolipoprotein C-III play an important and complex role in plasma triglycerides metabolism, respectively, as inhibitor and activator of lipoprotein lipase. Triglycerides 102-115 apolipoprotein C2 Homo sapiens 12-56 15559550-7 2004 Finally, the fact that hypertriglyceridaemia is more frequently observed after certain immunosuppressive treatments may be partly caused by changes in the synthesis and elimination of triglycerides involving lipoprotein lipase or some apolipoproteins which serve as its cofactors (apoCII or apoCIII). Triglycerides 184-197 apolipoprotein C2 Homo sapiens 281-287 12799125-2 2003 Several indices related to apolipoproteins (apo) CII and CIII blood concentration have been proposed to reflect TG metabolism more accurately than the blood level of TG. Triglycerides 112-114 apolipoprotein C2 Homo sapiens 27-52 11812765-7 2002 However, we found the strongest evidence for linkage of triglyceride levels to chromosome 19q13.2, very close to the ApoC2/ApoE/ApoC1/ApoC4 gene cluster (LOD 2.56) in the screening study; the LOD increased to 3.16 in the extended study. Triglycerides 56-68 apolipoprotein C2 Homo sapiens 117-122 12079439-8 2002 The risk factor-adjusted odds ratio (OR) for CHD was 1.60 (95% CI: 1.31-1.94) per 1 mg/dl increment in Apo C(II), compared with a risk factor-adjusted OR of 1.05 (95% CI: 0.85-1.32) per 40 mg/dl increment in triglyceride concentration. Triglycerides 208-220 apolipoprotein C2 Homo sapiens 103-112 8647097-1 1996 The hydrolysis of triacylglycerols of chylomicrons and very low density lipoproteins by lipoprotein lipase (LPL) requires the presence of apolipoprotein (apo) CII as a cofactor. Triglycerides 18-34 apolipoprotein C2 Homo sapiens 138-162 12517327-12 2002 In both groups, triglycerides levels were positively correlated with Apo E (p=0.0429), Apo C2 (p=0.0045) and Apo C3 (p=0.0004) concentrations, but not with Apo E/Apo C2 ratio (p=0.760). Triglycerides 16-29 apolipoprotein C2 Homo sapiens 87-93 12517327-12 2002 In both groups, triglycerides levels were positively correlated with Apo E (p=0.0429), Apo C2 (p=0.0045) and Apo C3 (p=0.0004) concentrations, but not with Apo E/Apo C2 ratio (p=0.760). Triglycerides 16-29 apolipoprotein C2 Homo sapiens 162-168 11286640-4 2001 Although rare mutations in lipoprotein lipase (LPL), the major TG-hydrolyzing enzyme, and apo CII (APOC2), its essential activator, result in extremely high plasma TG levels, their low frequency means they have little impact upon TG levels in the general population. Triglycerides 164-166 apolipoprotein C2 Homo sapiens 90-97 11286640-4 2001 Although rare mutations in lipoprotein lipase (LPL), the major TG-hydrolyzing enzyme, and apo CII (APOC2), its essential activator, result in extremely high plasma TG levels, their low frequency means they have little impact upon TG levels in the general population. Triglycerides 164-166 apolipoprotein C2 Homo sapiens 99-104 8647097-8 1996 A polyclonal antibody specific for apo CII impaired their ability to hydrolyse triacylglycerol emulsions. Triglycerides 79-94 apolipoprotein C2 Homo sapiens 35-42 8847480-10 1995 Some of the fibrates, especially gemfibrozil also reduced plasma apoC-II levels, an effect that could contribute to the observed triglyceride-lowering effect. Triglycerides 129-141 apolipoprotein C2 Homo sapiens 65-72 8847480-11 1995 In addition, the ratio of plasma apoE to plasma apoC-II plus apoC-III was strongly and inversely correlated with plasma triglyceride levels. Triglycerides 120-132 apolipoprotein C2 Homo sapiens 48-55